When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Bristol-Myers Squibb (BMY) is under considerable pressure, the stock has declined by more than 25% from its highs of the year due to generalized negativity towards the drug manufacturing sector and the uncertainty produced by the Celgene (CELG) acquisition.
On the other hand, the business remains fundamentally solid, and the stock is attractively valued at current levels. The risk versus reward trade-off in Bristol-Myers Squibb looks clearly convenient going forward.
The Fundamentals Remain Solid
In spite of the risk factors affecting Bristol-Myers Squibb in the middle term, the most recent financial